Pharmacology and Therapeutics - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/178

Filters

2006 - 2009 2
Reset filters

Settings
Statistics
Citations
Type: Journal Article × Start date: 2006 × End date: 2009 × Author: Adlard, Paul ×

Search Results

Now showing 1 - 2 of 2
  • Item
    No Preview Available
    Metals and Alzheimer's disease
    Adlard, PA ; Bush, AI (IOS PRESS, 2006-11)
    There is increasing evidence to support a role for both the amyloid beta-protein precursor (AbetaPP) and its proteolytic fragment, amyloid beta (Abeta), in metal ion homeostasis. Furthermore, metal ions such as zinc and copper can interact with both AbetaPP and Abeta to potentiate Alzheimer's disease by participating in the aggregation of these normal cellular proteins and in the generation of reactive oxygen species. In addition, metal ions may interact on several other AD-related pathways, including those involved in neurofibrillary tangle formation, secretase cleavage of AbetaPP and proteolytic degradation of Abeta. As such, a dysregulation of metal ion homeostasis, as occurs with both aging and in AD, may foster an environment that can both precipitate and accelerate degenerative conditions such as AD. This offers a broad biochemical front for novel therapeutic interventions.
  • Item
    Thumbnail Image
    Pharmacotherapeutic targets in Alzheimer's disease
    Biran, Y ; Masters, CL ; Barnham, KJ ; Bush, AI ; Adlard, PA (WILEY, 2009-01)
    Alzheimer's disease (AD) is a progressive neurodegenerative disorder which is characterized by an increasing impairment in normal memory and cognitive processes that significantly diminishes a person's daily functioning. Despite decades of research and advances in our understanding of disease aetiology and pathogenesis, there are still no effective disease-modifying drugs available for the treatment of AD. However, numerous compounds are currently undergoing pre-clinical and clinical evaluations. These candidate pharma-cotherapeutics are aimed at various aspects of the disease, such as the microtubule-associated tau-protein, the amyloid-beta(Abeta) peptide and metal ion dyshomeostasis--all of which are involved in the development and progression of AD. We will review the way these pharmacological strategies target the biochemical and clinical features of the disease and the investigational drugs for each category.